TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3043945

Group type: EXPERIMENTAL
Intervention: Iopromid (Ultravist)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ioglicinate (Rayvist)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ioxaglinate (Hexabrix)
Number of subjects: 46
Study: 31826241

Group type: EXPERIMENTAL
Intervention: Midostaurin
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: ELN favorable‐risk group
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Lower WBC counts
Number of subjects: 549
Study: 31248458

Group type: EXPERIMENTAL
Intervention: Multi-targeted kinase inhibitors after immune checkpoint inhibitors
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy following immune checkpoint inhibitors
Number of subjects: 6
Study: 28379519

Group type: EXPERIMENTAL
Intervention: Continuous infusion of GLP-1, OXM, and PYY (GOP) at doses of 4 pmol/kg/min for GLP-1 and OXM, and 0.4 pmol/kg/min for PYY
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26659941

Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005% plus Betamethasone Dipropionate 0.064% aerosol foam
Number of subjects: 426

Group type: COMPARATOR
Intervention: Vehicle aerosol foam
Number of subjects: 426
Study: 23036625

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 20
Study: 20059594

Group type: COMPARATOR
Intervention: Nitrous oxide and oxygen (Method A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nitrous oxide, sevoflurane, and oxygen (Method B)
Number of subjects: 30
Study: 17899135

Group type: COMPARATOR
Intervention: Extraction drilling
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Compaction drilling
Number of subjects: 26
Study: 15947624

Group type: EXPERIMENTAL
Intervention: Decreasing fluid intake in IDO group
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Decreasing fluid intake in USI group
Number of subjects: 110

Group type: COMPARATOR
Intervention: Caffeine restriction (changing from caffeine containing to decaffeinated drinks)
Number of subjects: 110
Study: 12838298

Group type: EXPERIMENTAL
Intervention: Oral antibiotics (ciprofloxacin 750 mg 12 hourly + amoxicillin-clavulanate 675 mg 8 hourly for 5 days)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Intravenous antibiotics (gentamicin and tazocin until hospital discharge)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Oral antibiotics
Number of subjects: 102

Group type: COMPARATOR
Intervention: Intravenous antibiotics
Number of subjects: 102
Study: 10809399

Group type: EXPERIMENTAL
Intervention: Transbond XT (n = 8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Phase II (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Transbond XT with liquid resin (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Phase II with liquid resin (n = 8)
Number of subjects: 16
Study: 8877673

Group type: EXPERIMENTAL
Intervention: moexipril 7.5 mg/day (in addition to hydrochlorothiazide 25 mg/day)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: verapamil SR 180 mg/day (in addition to hydrochlorothiazide 25 mg/day)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: moexipril 15 mg/day (after dose increase for patients with SDBP of > or = 90 mmHg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: verapamil SR 240 mg/day (after dose increase for patients with SDBP of > or = 90 mmHg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Combination of moexipril or verapamil SR with low-dose hydrochlorothiazide
Number of subjects: 108
Study: 1815115

Group type: EXPERIMENTAL
Intervention: 1% methohexital solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 mg/kg methohexital
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspiration of residual methohexital
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% methohexital solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: 15 mg/kg methohexital
Number of subjects: 0
Study: 6222545

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate treatment
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sequential therapy according to Hammerstein
Number of subjects: 46
Study: 30995665

Group type: EXPERIMENTAL
Intervention: Chromogranin A (CgA) measurement using NEOLISATM kit (EuroDiagnostica)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Chromogranin A (CgA) measurement
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Monitoring CgA levels over 12 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: CgA levels in non-neoplastic diseases (COPD and IPF)
Number of subjects: 200

Group type: COMPARATOR
Intervention: CgA levels in neoplastic diseases (NSCLC, SCC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: CgA levels in neuroendocrine SCLC
Number of subjects: 200
Study: 29856472

Group type: EXPERIMENTAL
Intervention: TXYF granules
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 26708331

Group type: EXPERIMENTAL
Intervention: Attention Training Technique (ATT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No-intervention condition
Number of subjects: 100
Study: 24185114

Group type: EXPERIMENTAL
Intervention: NASHA hyaluronic acid
Number of subjects: 442

Group type: COMPARATOR
Intervention: methylprednisolone acetate (MPA)
Number of subjects: 442
Study: 22988687

Group type: EXPERIMENTAL
Intervention: Test paste (8% arginine and calcium carbonate)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control paste (Nupro non-fluoridated pumice based prophylaxis paste)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Comparison between Test and Control pastes
Number of subjects: 66
Study: 20052358

Group type: EXPERIMENTAL
Intervention: Ulinastatin (300,000 IU)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 17912104

Group type: EXPERIMENTAL
Intervention: Biotène Oral Balance gel and toothpaste used daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Carboxymethylcellulose gel and Oral-B toothpaste (control)
Number of subjects: 36
Study: 16221568

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12196654

Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) recordings
Number of subjects: 33
Study: 10645799

Group type: EXPERIMENTAL
Intervention: PEM regimen (cisplatin 60 mg/m2 on day 1, etoposide 40 mg/m2 on days 1, 2, and 3, mitomycin-C 7 mg/m2 on day 1)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Long CF regimen (cisplatin 8 mg/m2 on days 1-5, 8-12, 15-19, and 22-26, 5-fluorouracil 300 mg/m2 as a 24 h infusion or oral UFT-E 400 mg/m2 on days 1-28)
Number of subjects: 26
Study: 8682929

Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR) procedure with e‐PFTE membrane placement
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conservative treatment modality (control) without e‐PFTE membrane placement
Number of subjects: 11
Study: 2269802

Group type: EXPERIMENTAL
Intervention: Self-report measures (Oucher and Analogue Chromatic Continuous Scale)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Behavioral measures (Children's Hospital of Eastern Ontario Pain Scale, CHEOPS)
Number of subjects: 25
Study: 7438383

Group type: EXPERIMENTAL
Intervention: Aspirin (1.0 g daily)
Number of subjects: 4524

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4524
Study: 31364036

Group type: EXPERIMENTAL
Intervention: SF-6D
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 155
Study: 29251980

Group type: EXPERIMENTAL
Intervention: Simulated bar context condition
Number of subjects: 143

Group type: COMPARATOR
Intervention: Neutral context condition
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Both conditions (simulated bar and neutral)
Number of subjects: 143
Study: 26153159

Group type: EXPERIMENTAL
Intervention: Sesame lignans and vitamin E (SVE)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 72
Study: 23522341

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 0
Study: 21460508

Group type: EXPERIMENTAL
Intervention: Daily bathing with chlorhexidine gluconate (CHG) using CHG-impregnated cloths
Number of subjects: 14801

Group type: COMPARATOR
Intervention: Daily bathing with soap and water
Number of subjects: 14801
Study: 18656274

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab bolus
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Intravenous abciximab bolus
Number of subjects: 1005
Study: 17330512

Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich vitamin E (TRE) 80 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich vitamin E (TRE) 160 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich vitamin E (TRE) 320 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 12956745

Group type: EXPERIMENTAL
Intervention: Induced sputum T cell stimulation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (non-asthmatics)
Number of subjects: 32
Study: 11112128

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (200 microg, twice a day for 7 or 8 days)
Number of subjects: 16
Study: 9169965

Group type: EXPERIMENTAL
Intervention: Risperidone (2, 6, 10, or 16 mg/day)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Risperidone (6 mg/day)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Risperidone (16 mg/day)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Haloperidol (20 mg/day)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study: 8230337

Group type: EXPERIMENTAL
Intervention: Tube thoracostomy (n = 19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Observation (n = 21)
Number of subjects: 40
Study: 3782046

Group type: EXPERIMENTAL
Intervention: Haloperidol (flexible dose)
Number of subjects: 22
Study: 31740427

Group type: EXPERIMENTAL
Intervention: Novel treatment (specifics not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical control data
Number of subjects: 0
Study: 29439973

Group type: EXPERIMENTAL
Intervention: DS-2969b (60 mg, 200 mg, 400 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 27400997

Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D weekly for 16 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 80
Study: 24557009

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Time/attention control
Number of subjects: 55
Study: 21993377

Group type: EXPERIMENTAL
Intervention: Self-administered intraperitoneal bemiparin (BM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 20534324

Group type: EXPERIMENTAL
Intervention: Obese individuals
Number of subjects: 180
Study: 19033019

Group type: EXPERIMENTAL
Intervention: Radionuclide angiography (RNA)
Number of subjects: 2521

Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 2521

Group type: EXPERIMENTAL
Intervention: Contrast angiography
Number of subjects: 2521

Group type: COMPARATOR
Intervention: RNA vs Echocardiography
Number of subjects: 2521

Group type: COMPARATOR
Intervention: RNA vs Contrast Angiography
Number of subjects: 2521

Group type: COMPARATOR
Intervention: Echocardiography vs Contrast Angiography
Number of subjects: 2521
Study: 17081396

Group type: EXPERIMENTAL
Intervention: TMLR/OPCAB (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: OPCAB (n = 40)
Number of subjects: 80
Study: 14980919

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (40 mg)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Thiopental 0.25 mg/kg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Thiopental 0.5 mg/kg
Number of subjects: 124
Study: 11710599

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (HFX RT) alone
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (HFX RT) with concurrent low-dose, daily cisplatin (CDDP)
Number of subjects: 130
Study: 9329791

Group type: EXPERIMENTAL
Intervention: Hyperlipidemia (DM‐HTG and DM‐HLP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperlipidemia (DM‐HLP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls or diabetics with normal serum lipids
Number of subjects: 0
Study: 8201562

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren Ophthalmic)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 148
Study: 3302004

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg at night
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cimetidine 400 mg at night
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg at night (open evaluation)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 44
Study: 28986942

Group type: EXPERIMENTAL
Intervention: Aroma-massage with acupressure + exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aroma-massage with acupressure + cognitive training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cognitive training + exercise
Number of subjects: 60
Study: 27484695

Group type: EXPERIMENTAL
Intervention: Tissue perfusion-guided treatment strategy based on capillary refill time, peripheral temperature, arterial lactate concentrations, and lower MAP levels.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Macrocirculation target-guided standard care.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tissue perfusion-guided treatment strategy
Number of subjects: 200
Study: 23677960

Group type: EXPERIMENTAL
Intervention: Palmar fixed-angle plate fixation
Number of subjects: 40

Group type: COMPARATOR
Intervention: K-wire fixation
Number of subjects: 40
Study: 23751736

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 39
Study: 20925617

Group type: EXPERIMENTAL
Intervention: Laparoscopy followed by ovarian stimulation and timed intercourse for six cycles
Number of subjects: 512

Group type: COMPARATOR
Intervention: Ovarian stimulation and timed intercourse for six cycles
Number of subjects: 512
Study: 17988905

Group type: EXPERIMENTAL
Intervention: Standardised 3% polidocanol foam
Number of subjects: 106

Group type: COMPARATOR
Intervention: 3% liquid polidocanol
Number of subjects: 106
Study: 16344278

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 97

Group type: COMPARATOR
Intervention: Mayo regimen (i.v. 5-FU/LV)
Number of subjects: 97

Group type: COMPARATOR
Intervention: OPdG (i.v. 5-FU/LV)
Number of subjects: 97
Study: 14594790

Group type: COMPARATOR
Intervention: 0 mg Fe (control)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 100 mg Fe
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 400 mg Fe
Number of subjects: 11
Study: 10916520

Group type: EXPERIMENTAL
Intervention: Increased skim or 1% milk intake by 3 cups per day (n = 101)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Maintain usual diet (n = 103)
Number of subjects: 204
Study: 8727861

Group type: EXPERIMENTAL
Intervention: Dipstick screening for hematuria
Number of subjects: 659

Group type: COMPARATOR
Intervention: No dipstick screening for hematuria (hematuria-negative)
Number of subjects: 659
Study: 1550148

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 in a controlled-release vaginal pessary
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 3895595

Group type: EXPERIMENTAL
Intervention: MaxEpa (fish oil concentrate)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 11
Study: 29728858

Group type: EXPERIMENTAL
Intervention: ceramide complex cream
Number of subjects: 39

Group type: COMPARATOR
Intervention: placebo cream
Number of subjects: 39
Study: 26814686

Group type: EXPERIMENTAL
Intervention: Ambrisentan (endothelin antagonist)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 23713836

Group type: EXPERIMENTAL
Intervention: context-focused therapy
Number of subjects: 41
Study: 22226683

Group type: EXPERIMENTAL
Intervention: Extreme hypofractionated radiotherapy (35 Gy in five fractions)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: First two fractions of treatment
Number of subjects: 53
Study: 20038728

Group type: EXPERIMENTAL
Intervention: Acupuncture (12 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Venlafaxine (12 weeks)
Number of subjects: 50
Study: 19100066

Group type: EXPERIMENTAL
Intervention: Thiazide diuretics (n = 200)
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Losartan (n = 324)
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Losartan + Hydrochlorothiazide (Hyzaar, n = 476)
Number of subjects: 1080
Study: 15638942

Group type: EXPERIMENTAL
Intervention: Clinician's assessment of cough quality (wet/dry)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Clinician's cough assessment compared to bronchoscopy (bronchoscopic secretion grade 4)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: ROC curve for cough quality related to airway secretions
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Intra-observer agreement for wet/dry cough
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Inter-clinician agreement for wet/dry cough
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Inter-rater agreement for bronchoscopic secretion grades
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity for brassy cough (for tracheomalacia)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Intra and inter-observer clinician agreement for brassy cough
Number of subjects: 106
Study: 12902410

Group type: EXPERIMENTAL
Intervention: (99m)Tc-tetrofosmin SPECT
Number of subjects: 83

Group type: COMPARATOR
Intervention: CT
Number of subjects: 83
Study: 10507245

Group type: EXPERIMENTAL
Intervention: Metrifonate 50 mg tablet administered in fasting condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metrifonate 50 mg tablet administered after high-fat/high-calorie breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metrifonate 80 mg tablet administered at 8:00 a.m. after overnight fasting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metrifonate 80 mg tablet administered at 7:00 p.m. (7 h after lunch)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metrifonate 80 mg tablet administered at 10:00 p.m. (4 h after dinner)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metrifonate administration (all studies)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metrifonate administration with food
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metrifonate administration at different times (morning vs evening)
Number of subjects: 0
Study: 7856894

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both anesthetics
Number of subjects: 20
Study: 2026286

Group type: EXPERIMENTAL
Intervention: Hearing aid with most midfrequency amplification
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hearing aid with intermediate midfrequency gain
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Speech Intelligibility Rating Test (SIR) results
Number of subjects: 13
Study: 6798601

Group type: EXPERIMENTAL
Intervention: Morphine (10 mg/70 kg body weight)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 20
Study: 31514108

Group type: EXPERIMENTAL
Intervention: Kinesiology taping with exercise
Number of subjects: 34

Group type: COMPARATOR
Intervention: Exercise without kinesiology taping
Number of subjects: 34
Study: 27966722

Group type: EXPERIMENTAL
Intervention: Coconut oil (CO) 22.25 g
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Coconut oleogel (CG) 25 g
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (orange juice and rice porridge)
Number of subjects: 16
Study: 26421692

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR) training for 8 weeks (approximately 20 hours)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) for 8 weeks
Number of subjects: 56
Study: 23389113

Group type: EXPERIMENTAL
Intervention: Diurnal carbohydrate/nocturnal protein (DCNP)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Nocturnal carbohydrate/diurnal protein (NCDP)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control diet (CT)
Number of subjects: 58
Study: 22317004

Group type: EXPERIMENTAL
Intervention: Safety device plus workshop
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Workshop only
Number of subjects: 796

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 796
Study: 19241773

Group type: EXPERIMENTAL
Intervention: Bromfenac 0.09% twice daily
Number of subjects: 212

Group type: COMPARATOR
Intervention: Ketorolac 0.4% four times daily
Number of subjects: 212
Study: 17143108

Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate
Number of subjects: 5
Study: 15341981

Group type: EXPERIMENTAL
Intervention: Docetaxel (40 mg/m2 weekly infusion)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Methotrexate (40 mg/m2 weekly bolus i.v. injection)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Overall survival and time to progression
Number of subjects: 57
Study: 11599317

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 45
Study: 10919587

Group type: EXPERIMENTAL
Intervention: Isradipine (Lomir)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 8795768

Group type: EXPERIMENTAL
Intervention: Slit-lamp biomicroscopy with Volk 60 D lens
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Slit-lamp biomicroscopy with Volk 90 D lens
Number of subjects: 25

Group type: COMPARATOR
Intervention: Heidelberg Retina Tomograph
Number of subjects: 25